These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37983691)

  • 1. Should Bone Turnover Markers Be Used Routinely to Monitor Oral Bisphosphonate Osteoporosis Therapy? Yes: Measuring Adherence and Effectiveness of Therapy Benefits Patients.
    Doshi KB; Khan LZ
    Am Fam Physician; 2023 Nov; 108(5):442-443. PubMed ID: 37983691
    [No Abstract]   [Full Text] [Related]  

  • 2. Should Bone Turnover Markers Be Used Routinely to Monitor Oral Bisphosphonate Osteoporosis Therapy? No: Measurement Is Unnecessary and a Poor Use of Medical Resources.
    Muncie HL; Mohr DJ; Maras ML
    Am Fam Physician; 2023 Nov; 108(5):444-446. PubMed ID: 37983692
    [No Abstract]   [Full Text] [Related]  

  • 3. Bone turnover markers to monitor oral bisphosphonate therapy.
    Ashcherkin N; Patel AA; Algeciras-Schimnich A; Doshi KB
    Cleve Clin J Med; 2023 Jan; 90(1):26-31. PubMed ID: 36596600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
    Naylor KE; Jacques RM; Paggiosi M; Gossiel F; Peel NF; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis.
    Lorentzon M; Branco J; Brandi ML; Bruyère O; Chapurlat R; Cooper C; Cortet B; Diez-Perez A; Ferrari S; Gasparik A; Herrmann M; Jorgensen NR; Kanis J; Kaufman JM; Laslop A; Locquet M; Matijevic R; McCloskey E; Minisola S; Pikner R; Reginster JY; Rizzoli R; Szulc P; Vlaskovska M; Cavalier E
    Adv Ther; 2019 Oct; 36(10):2811-2824. PubMed ID: 31440982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.
    Diez-Perez A; Naylor KE; Abrahamsen B; Agnusdei D; Brandi ML; Cooper C; Dennison E; Eriksen EF; Gold DT; Guañabens N; Hadji P; Hiligsmann M; Horne R; Josse R; Kanis JA; Obermayer-Pietsch B; Prieto-Alhambra D; Reginster JY; Rizzoli R; Silverman S; Zillikens MC; Eastell R;
    Osteoporos Int; 2017 Mar; 28(3):767-774. PubMed ID: 28093634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
    Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
    Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice.
    Weycker D; Lamerato L; Schooley S; Macarios D; Siu Woodworth T; Yurgin N; Oster G
    Osteoporos Int; 2013 Apr; 24(4):1483-9. PubMed ID: 22903292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Szulc P
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):908-923. PubMed ID: 28689768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
    Martens MG; Shaw H
    South Med J; 2008 Aug; 101(8):824-30. PubMed ID: 18622322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis.
    Naylor KE; McCloskey EV; Jacques RM; Peel NFA; Paggiosi MA; Gossiel F; Walsh JS; Eastell R
    Osteoporos Int; 2019 Apr; 30(4):917-922. PubMed ID: 30613868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review.
    Fardellone P; Lello S; Cano A; de Sá Moreira E; Watanabe de Oliveira R; Julian GS; Tang B
    Clin Ther; 2019 Aug; 41(8):1576-1588. PubMed ID: 31151814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS; Chua SS; Chew YY; Chan SP
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
    Matsumoto T; Hagino H; Shiraki M; Fukunaga M; Nakano T; Takaoka K; Morii H; Ohashi Y; Nakamura T
    Osteoporos Int; 2009 Aug; 20(8):1429-37. PubMed ID: 19101754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is a 'failure' of bisphosphonate therapy for osteoporosis?
    Carey JJ
    Cleve Clin J Med; 2005 Nov; 72(11):1033-9. PubMed ID: 16315442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.